Evidence map›Paper›PMID 38946554›Full record

ArticleJournal of the American Medical Informatics Association : JAMIA2025

Reducing diagnostic delays in acute hepatic porphyria using health records data and machine learning.

Balu Bhasuran, Katharina Schmolly, Yuvraaj Kapoor, Nanditha Lakshmi Jayakumar, Raymond Doan, Jigar Amin, Stephen Meninger, Nathan Cheng, Robert Deering, Karl Anderson and 3 more

Abstract read
In one paragraph

Article in Journal of the American Medical Informatics Association : JAMIA, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Leveraging artificial intelligence to reduce diagnostic errors in emergency medicine: Challenges, opportunities, and future directions.Academic emergency medicine : official journal of the Society for Academic Emergency Medicine · 2025
    Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

13 authors.

Balu BhasuranBakar Computational Health Sciences Institute, University of California, San Francisco, San Francisco, CA 94143, United States.ORCID 0000-0002-9890-4627
Katharina SchmollyDavid Geffen School of Medicine & Pfleger Liver Institute, University of California Los Angeles, Los Angeles, CA 90095, United States.ORCID 0000-0002-6034-5620
Yuvraaj KapoorDivision of Gastroenterology, Department of Medicine, University of California, San Francisco, San Francisco, CA 94143, United States.
Nanditha Lakshmi JayakumarDivision of Gastroenterology, Department of Medicine, University of California, San Francisco, San Francisco, CA 94143, United States.
Raymond DoanAlnylam Pharmaceuticals, Cambridge, MA 02142, United States.
Jigar AminAlnylam Pharmaceuticals, Cambridge, MA 02142, United States.
Stephen MeningerAlnylam Pharmaceuticals, Cambridge, MA 02142, United States.
Nathan ChengAlnylam Pharmaceuticals, Cambridge, MA 02142, United States.
Robert DeeringAlnylam Pharmaceuticals, Cambridge, MA 02142, United States.
Karl AndersonDivision of Gastroenterology and Hepatology, University of Texas Medical Branch, School of Medicine, Galveston, TX 77555, United States.ORCID 0000-0002-6499-8573
Simon W BeavenDavid Geffen School of Medicine & Pfleger Liver Institute, University of California Los Angeles, Los Angeles, CA 90095, United States.ORCID 0000-0002-9511-1576
Bruce WangDivision of Gastroenterology, Department of Medicine, University of California, San Francisco, San Francisco, CA 94143, United States.ORCID 0000-0003-3486-5494
Vivek A RudrapatnaBakar Computational Health Sciences Institute, University of California, San Francisco, San Francisco, CA 94143, United States.ORCID 0000-0003-1789-3004

Funding

UCLA Clinical Translational Science InstituteUL1TR001881 · NCATS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI ARLEEN F. BROWN, ARASH NAEIM · 2016 to 2026
$118.1M
Clinical and Translational Science InstituteUL1TR001872 · NCATS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI COLLARD, HAROLD R, JACOBY, VANESSA · 2016 to 2025
$112.1M
National Library of Medicine of the National Institutes of Health K99LM014099NCATS NIH HHS UL1 TR001872NCATS NIH HHS UL1 TR001881
6 · The paper itself

Abstract

backgroundAcute hepatic porphyria (AHP) is a group of rare but treatable conditions associated with diagnostic delays of 15 years on average. The advent of electronic health records (EHR) data and machine learning (ML) may improve the timely recognition of rare diseases like AHP. However, prediction models can be difficult to train given the limited case numbers, unstructured EHR data, and selection biases intrinsic to healthcare delivery. We sought to train and characterize models for identifying patients with AHP.

methodsThis diagnostic study used structured and notes-based EHR data from 2 centers at the University of California, UCSF (2012-2022) and UCLA (2019-2022). The data were split into 2 cohorts (referral and diagnosis) and used to develop models that predict (1) who will be referred for testing of acute porphyria, among those who presented with abdominal pain (a cardinal symptom of AHP), and (2) who will test positive, among those referred. The referral cohort consisted of 747 patients referred for testing and 99 849 contemporaneous patients who were not. The diagnosis cohort consisted of 72 confirmed AHP cases and 347 patients who tested negative. The case cohort was 81% female and 6-75 years old at the time of diagnosis. Candidate models used a range of architectures. Feature selection was semi-automated and incorporated publicly available data from knowledge graphs. Our primary outcome was the F-score on an outcome-stratified test set.

resultsThe best center-specific referral models achieved an F-score of 86%-91%. The best diagnosis model achieved an F-score of 92%. To further test our model, we contacted 372 current patients who lack an AHP diagnosis but were predicted by our models as potentially having it (≥10% probability of referral, ≥50% of testing positive). However, we were only able to recruit 10 of these patients for biochemical testing, all of whom were negative. Nonetheless, post hoc evaluations suggested that these models could identify 71% of cases earlier than their diagnosis date, saving 1.2 years.

conclusionsML can reduce diagnostic delays in AHP and other rare diseases. Robust recruitment strategies and multicenter coordination will be needed to validate these models before they can be deployed.

Indexed as

Delayed DiagnosisElectronic Health RecordsMachine LearningPorphyrias, HepaticAdolescentAdultFemaleHumansMaleMiddle AgedPorphobilinogen SynthaseReferral and ConsultationYoung AdultPorphobilinogen Synthaseacute hepatic porphyriaelectronic health records dataknowledge graphsmachine learningrare disease prediction

Identifiers

PMID38946554
PMCPMC11648717

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.